Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer.
Tumori
; 104(6): NP29-NP33, 2018 Dec.
Article
in En
| MEDLINE
| ID: mdl-30392443
ABSTRACT
INTRODUCTION:
Treatment paradigms for EGFR-mutated non-small cell lung cancer (NSCLC) have successfully evolved since the introduction of osimertinib. The detection of EGFR T790M mutation in plasma or tumor samples obtained at disease progression to first-/second-generation EGFR inhibitors is mandatory for osimertinib prescription. Nevertheless, pharmacokinetics properties of osimertinib guarantee its usefulness in central nervous system (CNS) disease even in the case of T790M-negative or unknown status. PATIENTS ANDMETHODS:
In this brief report, we share the clinical histories of two patients with CNS-preeminent progression under first-/second-generation EGFR inhibitors in which it was not possible to document the presence of T790M resistance mutation.RESULTS:
Patient outcomes diverged dramatically due to the differential availability of off-label osimertinib.CONCLUSIONS:
Waiting for the novel molecule to be approved and licensed in first-line treatment, our report of hope and frustration is intended to stress the opportunity of its administration in the case of CNS failure of first-line EGFR inhibition, even in the absence of T790M proof.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acrylamides
/
Central Nervous System
/
Carcinoma, Non-Small-Cell Lung
/
Aniline Compounds
/
Lung Neoplasms
/
Mutation
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Tumori
Year:
2018
Document type:
Article
Affiliation country:
Italy
Country of publication:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA